Notably, recent work using uPA-targeted dendrimer gel nanoparticles to deliver the antisense oligonucleotide GTI-2040 against ribonucleotide reductase R2 in triple-negative breast cancer exemplifies how uPA/uPAR targeting combined with engineered carrier chemistry produces marked increases in cellular delivery, robust target knockdown, and significant tumor growth inhibition, indicating a practical path to translate uPAR-albumin design principles into effective therapies [60]. The gene discussed is PLAUR; the disease is triple-negative breast carcinoma.